8-K

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                       Pursuant to Section 13 or 15(d) of
                      The Securities Exchange Act of 1934



        Date of Report (date of earliest event reported): March 3, 2004


                          Commission File No. 0-11178
                                              -------


                          UTAH MEDICAL PRODUCTS, INC.
             (Exact name of Registrant as specified in its charter)


                      UTAH                                87-0342734
         -------------------------------             ------------------
         (State or other jurisdiction of               (I.R.S. Employer
         incorporation or organization)               Identification No.)


                              7043 South 300 West
                              Midvale, Utah 84047
                     Address of principal executive offices


Registrant's telephone number:      (801) 566-1200
                                    --------------







- -------------------------------------------------------------------------------
                        ITEM 9. REGULATION FD DISCLOSURE
- -------------------------------------------------------------------------------


On March 4, 2004, Utah Medical Products,  Inc. issued a press release, a copy of
which is attached hereto as Exhibit 99.1



- -------------------------------------------------------------------------------
                                   SIGNATURES
- -------------------------------------------------------------------------------

Pursuant  to the  requirements  of the  Securities  Exchanges  Act of 1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                                UTAH MEDICAL PRODUCTS, INC.
                                                ---------------------------
                                                REGISTRANT


Date:     3/4/2004                             By:  /s/ Kevin L. Cornwell
- -----------------------------                   ---------------------------
                                                    Kevin L. Cornwell
                                                    CEO




- --------------------------------------------------------------------------------

                                  EXHIBIT INDEX



Index
Number  Description
        -----------

99.1    Press release issued March 4, 2004: Utah Medical Products, Inc. Reports
        Conclusion of FDA Inspection.

EX-99.1

                                  EXHIBIT 99.1

Salt Lake City, Utah - On February 11, Utah Medical Products, Inc. (NASDAQ:
UTMD) publicly disclosed a comprehensive inspection of its Utah facility by
three FDA inspectors from Minneapolis, Dallas and Denver which began on February
2.

In response to shareholder questions regarding the status of the inspection,
UTMD announces that on March 3, the inspection ended with the presentation of
seven observations in a Form FDA-483, which the Company reviewed completely with
the inspectors. These observations relate to only 6 of more than 150 subsections
of the FDA Quality System Regulation (QSR). UTMD is now preparing a written
response to the FDA regarding the observations. The inspection, which consumed
56 inspector-days, reviewed many thousands of pages of quality system documents
including device history records, procedures, complaints and complaint
investigations, nonconformance reports, deviation/ waivers, corrective action
reports, process control records including statistical process control
parameters, meeting minutes, bills of operation, set-up sheets, calibration
reports, process validation records, sterilization records, test reports
including raw data and many other documents. Considering the extent of the
inspection, UTMD believes the observations are relatively few, easily explained
and some not supportable.

At the conclusion of the 2003 inspection by two inspectors for almost three
weeks, UTMD received a FDA-483 with 19 observations which relate to specific
subsections of the QSR. These observations were explicitly reviewed again in the
present inspection. Some of the key previous observations, for example, alleged
lack of proper sterilization validation where the Company's same documentation
was available to inspectors in 2002 and 2003 inspections, did not reappear on
the current FDA-483.

UTMD believes its longstanding position has been vindicated on the basis that
the adequacy of UTMD's QSR procedures that have been in existence for years has
been verified. There were no current observations to suggest or support concern
about the safety or effectiveness of any devices manufactured and distributed by
UTMD. This last statement represents to UTMD the continuing confirmation of the
effectiveness of the UTMD Quality System that has been in effect since prior to
the 2001 inspection which resulted in an FDA Warning Letter, and consistent with
the unqualified ISO certifications UTMD has enjoyed since 1994, long before the
FDA modified its GMP regulation to conform with the criteria and objectives of
the ISO. The ISO standards are quality system standards used by most countries
around the world including the U.S.

UTMD advises that its devices are of state of the art quality preferred in
particular by sophisticated clinician users, and that its devices conform to the
quality and performance represented by UTMD.

Investors are cautioned that this press release contains a forward looking
statement, and that actual results may differ from those projected. Risk factors
that could cause results to differ materially from those projected include FDA
reviewers' perspective of the observations noted on the 2004 FDA-483 and their
willingness to enter into a dialogue with the Company to resolve any
disagreements, which to date has not occurred since the 2002 inspection.





Utah Medical Products, Inc., with particular interest in health care for women
and their babies, develops, manufactures, assembles and markets a broad range of
disposable and reusable specialty medical devices designed for better health
outcomes for patients and their care-providers. For more information about Utah
Medical Products, Inc., visit UTMD's website at www.utahmed.com.
                                                ---------------